Abametapir Patent Expiration

Abametapir is Used for treating head lice infestation in patients 6 months of age and older. It was first introduced by Hatchtech Pty Ltd in its drug Xeglyze on Jul 24, 2020.


Abametapir Patents

Given below is the list of patents protecting Abametapir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xeglyze US10292389 Pediculicidal composition Dec 17, 2034 Hatchtech
Xeglyze US7812163 Methods and compositions for controlling ectoparasites Oct 28, 2026 Hatchtech
Xeglyze US8212038 Methods and compositions for controlling ectoparasites Jul 16, 2024

(Expired)

Hatchtech
Xeglyze US9357783 Methods and compositions for controlling ectoparasites Jul 16, 2024

(Expired)

Hatchtech
Xeglyze US9839631 Methods and compositions for controlling ectoparasites Jul 16, 2024

(Expired)

Hatchtech


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳